Taho Pharma Submits New Drug Application to US FDA for Apixaban Oral Dissolving Film - Cardiovascular News

TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world's first Apixaban Oral Dissolving Film (ODF). This…

Taho Pharma submits new drug application to US FDA for apixaban oral dissolving film - Cardiovascular News

Taho Pharmaceuticals has announced the submission of its new drug application (NDA) to the US Food and Drug Administration (FDA) for TAH3311, apixaban oral dissolving film (ODF). TAH3311 is an innovative formulation designed to improve the delivery of apixaban, a widely used anticoagulant. Developed on Taho’s proprietary transepithelial delivery system (TDS) platform, TAH3311 is formulated as an easy-to-use oral dissolving film (ODF). According …